Lilly believes it has two promising new molecules for diabetes and obesity. But which to choose – and might toxicity yet scupper one or both?
Response rates with zenocutuzumab hold up, but Elevation Oncology’s rival project looks similar.
The big pharma becomes the latest to look at IL-2 to harness regulatory T cells, but plenty of others have the same idea.
Trading well below cash hasn’t stopped Cullinan from extracting more from Otsuka, when a low-ball buyout might have been on the cards.
But it’s still far too early to tell whether combining Car-T with an mRNA vaccine might improve response durability.